Literature DB >> 22718542

Comparative effectiveness and implementation research: directions for neurology.

Barbara G Vickrey1, Deborah Hirtz, Salina Waddy, Eric M Cheng, S Claiborne Johnston.   

Abstract

There is an enormous unmet need for knowledge about how new insights from discovery and translational research can yield measurable, population-level improvements in health and reduction in mortality among those having or at risk for neurological disease. Once several, well-conducted randomized controlled trials establish the efficacy of a given therapy, implementation research can generate new knowledge about barriers to uptake of the therapy into widespread clinical care, and what strategies are effective in overcoming those barriers and in addressing health disparities. Comparative effectiveness research aims to elucidate the relative value (including clinical benefit, clinical harms, and/or costs) of alternative efficacious management approaches to a neurological disorder, generally through direct comparisons, and may include comparisons of methodologies for implementation. Congress has recently appropriated resources and established an institute to prioritize funding for such research. Neurologists and neuroscientists should understand the scope and objectives of comparative effectiveness and implementation research, their range of methodological approaches (formal literature syntheses, randomized trials, observational studies, modeling), and existing research resources (centers for literature synthesis, registries, practice networks) relevant to research for neurological conditions, to close the well-documented evidence-to-practice gap. Future directions include building this research resource capacity, producing scientists trained to conduct rigorous comparative effectiveness and implementation research, and embracing innovative strategies to set research priorities in these areas.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Year:  2012        PMID: 22718542      PMCID: PMC3836834          DOI: 10.1002/ana.22672

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  44 in total

Review 1.  Designing and evaluating interventions to eliminate racial and ethnic disparities in health care.

Authors:  Lisa A Cooper; Martha N Hill; Neil R Powe
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

2.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

3.  Practice-based research--"Blue Highways" on the NIH roadmap.

Authors:  John M Westfall; James Mold; Lyle Fagnan
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

4.  Research agenda. Opportunities for research and NIH.

Authors:  Francis S Collins
Journal:  Science       Date:  2010-01-01       Impact factor: 47.728

5.  IOM task impossible: set the agenda for neurological comparative effectiveness research.

Authors:  S Claiborne Johnston; Stephen L Hauser
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

Review 6.  Speech and language therapy for aphasia following stroke.

Authors:  J Greener; P Enderby; R Whurr
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Underutilization of therapy for hepatocellular carcinoma in the medicare population.

Authors:  Shimul A Shah; Jillian K Smith; Youfu Li; Sing Chau Ng; James E Carroll; Jennifer F Tseng
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

8.  Central challenges facing the national clinical research enterprise.

Authors:  Nancy S Sung; William F Crowley; Myron Genel; Patricia Salber; Lewis Sandy; Louis M Sherwood; Stephen B Johnson; Veronica Catanese; Hugh Tilson; Kenneth Getz; Elaine L Larson; David Scheinberg; E Albert Reece; Harold Slavkin; Adrian Dobs; Jack Grebb; Rick A Martinez; Allan Korn; David Rimoin
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

9.  NIH disease funding levels and burden of disease.

Authors:  Leslie A Gillum; Christopher Gouveia; E Ray Dorsey; Mark Pletcher; Colin D Mathers; Charles E McCulloch; S Claiborne Johnston
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

10.  Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI Series.

Authors:  Cheryl B Stetler; Brian S Mittman; Joseph Francis
Journal:  Implement Sci       Date:  2008-02-15       Impact factor: 7.327

View more
  6 in total

1.  Accuracy of claims-based algorithms for epilepsy research: Revealing the unseen performance of claims-based studies.

Authors:  Lidia M V R Moura; Maggie Price; Andrew J Cole; Daniel B Hoch; John Hsu
Journal:  Epilepsia       Date:  2017-02-15       Impact factor: 5.864

Review 2.  Priorities in pediatric epilepsy research: improving children's futures today.

Authors:  Anne T Berg; Christine B Baca; Tobias Loddenkemper; Barbara G Vickrey; Dennis Dlugos
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

3.  Long-term seizure remission in childhood absence epilepsy: might initial treatment matter?

Authors:  Anne T Berg; Susan R Levy; Francine M Testa; Hal Blumenfeld
Journal:  Epilepsia       Date:  2014-02-11       Impact factor: 5.864

Review 4.  From Data to Action: Neuroepidemiology Informs Implementation Research for Global Stroke Prevention and Treatment.

Authors:  George A Mensah; Ralph L Sacco; Barbara G Vickrey; Uchechukwu K A Sampson; Salina Waddy; Bruce Ovbiagele; Jeyaraj Durai Pandian; Bo Norrving; Valery L Feigin
Journal:  Neuroepidemiology       Date:  2015-10-28       Impact factor: 3.282

Review 5.  The challenges and innovations for therapy in children with epilepsy.

Authors:  Jo M Wilmshurst; Anne T Berg; Lieven Lagae; Charles R Newton; J Helen Cross
Journal:  Nat Rev Neurol       Date:  2014-04-08       Impact factor: 42.937

Review 6.  Implementation Science to Improve Quality of Neurological Care.

Authors:  Debopam Samanta; Sara J Landes
Journal:  Pediatr Neurol       Date:  2021-05-15       Impact factor: 4.210

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.